Safety and therapeutic potential of M2-macrophages in stroke treatment.

Safety and therapeutic potential of M2-macrophages in stroke treatment. Cell Transplant. 2015 Dec 14; Authors: Chernykh ER, Shevela EY, Starostina NM, Morozov SA, Davydova MN, Menyaeva EV, Ostanin AA Abstract Our objective was to evaluate the safety and clinical efficacy of autologous M2 macrophage transplantation in non-acute stroke patients. We also evaluated whether the intrathecal administration of macrophages influences the production of cytokines by peripheral blood cells, and whether the levels of cytokines correlate with stroke severity and responsiveness to celltherapy. For this, thirteen patients (12 males and one female with median 63 years) diagnosed with ischemic (n=10) or hemorrhagic (n=3) stroke have been subjected to cell transplantation therapy (study group). On average 21.9 x 10(6) of autologous M2 macrophages were injected via intrathecal introduction. Thirteen matched case-control stroke patients who did not receive cell therapy formed the control group. We did not observe any serious adverse events, i.e. intrahospital mortality, neurological worsening and seizures, related to the cell injection. One patient in the study group and two patients in the control group died during the 6-mo follow-up period due to the recurrent stroke. In the study group the NIHSS score decreased from 11 to 6 (p=0.007) in 6 mo after the therapy, whereas the patients in the control group showed a less pronounced neurological improvement ...
Source: Cell Transplantation - Category: Cytology Authors: Tags: Cell Transplant Source Type: research